Department of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Department of Urology, Capital Medical University, Beijing Youan Hospital, Beijing, China.
Cancer Control. 2023 Jan-Dec;30:10732748231173475. doi: 10.1177/10732748231173475.
People living with HIV (PLWH) have a worse prognosis than the general population. Locally advanced or metastatic bladder cancer (BCa) in PLWH has gradually been increasing in recent years. Immune checkpoint inhibitors can improve antitumor activity in the general population, but relevant data in PLWH are unknown. We thus evaluated the efficacy and safety of tislelizumab in PLWH with locally advanced or metastatic BCa.
This retrospective study included 24 patients with locally advanced or metastatic BCa, both HIV positive or negative who underwent tislelizumab treatment (200 mg i.v. every 3 weeks, Q3W) from the multi-centers between December 2019 and March 2022. Demographic details, clinical data, and cancer status were collected. The overall survival (OS), progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), clinical benefit rate (CBR), and treatment-related adverse events (TRAEs) were recorded and evaluated.
A total of 24 individuals were chosen for this study, 10 had HIV and the other 14 did not. The median OS in the HIV-negative group was 62.3 (95% CI, 52.6 to 72.2) was no longer than that of the PLWH group 41.9 (95% CI, 32.9 to 51.0) weeks (HR .7, [95% CI, .17 to 3.30], = .70). Furthermore, the median PFS in the HIV-negative group was 50.0 (95% CI, 36.2 to 63.9) was also no longer than that of the PLWH group 35.9 (95% CI, 25.5 to 46.3) (HR, 1.34, [95% CI, .38 to 4.69], = .63). Of 24 patients, treatment-related adverse events, grade 3 or 4 occurred in 2 in the PLWH group and 3 in the HIV-negative group.
This retrospective multi-center study suggested that tislelizumab may provide encouraging antitumor activity and could be generally well tolerated. In this retrospective analysis of patients with locally advanced or metastatic BCa, it seems that PLWH may have similar overall and progression-free survival compared to HIV-negative cases.
HIV 感染者（PLWH）的预后比一般人群差。近年来，PLWH 中局部晚期或转移性膀胱癌（BCa）的发病率逐渐增加。免疫检查点抑制剂可提高一般人群的抗肿瘤活性，但 PLWH 相关数据尚不清楚。因此，我们评估了替雷利珠单抗在 PLWH 局部晚期或转移性 BCa 中的疗效和安全性。
这是一项回顾性研究，纳入了 2019 年 12 月至 2022 年 3 月期间在多中心接受替雷利珠单抗（200mg，静脉注射，每 3 周 1 次，Q3W）治疗的 24 例局部晚期或转移性 BCa 患者，包括 HIV 阳性和阴性患者。收集人口统计学特征、临床数据和癌症状态。记录并评估总生存期（OS）、无进展生存期（PFS）、客观缓解率（ORR）、疾病控制率（DCR）、临床获益率（CBR）和治疗相关不良事件（TRAEs）。
本研究共纳入 24 例患者，其中 10 例为 HIV 阳性，14 例为 HIV 阴性。HIV 阴性组的中位 OS 为 62.3（95%CI，52.6 至 72.2）周，短于 PLWH 组的 41.9（95%CI，32.9 至 51.0）周（HR.7，[95%CI，.17 至 3.30]， =.70）。此外，HIV 阴性组的中位 PFS 为 50.0（95%CI，36.2 至 63.9）周，也短于 PLWH 组的 35.9（95%CI，25.5 至 46.3）周（HR，1.34，[95%CI，.38 至 4.69]， =.63）。在 24 例患者中，PLWH 组有 2 例和 HIV 阴性组有 3 例发生治疗相关不良事件，均为 3 级或 4 级。
这项回顾性多中心研究表明，替雷利珠单抗可能具有令人鼓舞的抗肿瘤活性，且总体耐受性良好。在这项局部晚期或转移性 BCa 患者的回顾性分析中，PLWH 的总生存期和无进展生存期似乎与 HIV 阴性患者相似。
